Brandon Buck: Human Cell-Free DNA as a Diagnostic Tool for Aging and Rare Blood Disorders
Brandon Buck, Postdoctoral Research Fellow at Harvard Medical School, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Nature Progress Oncology, adding:
“Officially published my first-author Ph.D. manuscript on utilizing human blood plasma cell free DNA as a diagnostic tool for analyzing the telomeric and genomic landscape in aging and rare blood disorders.
Additionally, cell free DNA reveals unique telomeric chromatin footprints in vivo.
After numerous years of coding, data analysis, Illumina and Oxford Nanopore sequencing, CUTandRUN experiments, and cell free DNA isolations and library preps, the paper has been published, and a provisional patent has been submitted.
Please enjoy!”
Title: Fragmentation patterns of human telomeric chromatin in plasma cfDNA
Authors: Brandon Buck, Abigail Weirich, Stephanie Eramo, Rachel Lopez, Laura K. White, Peter Kabos, Craig Forester, Srinivas Ramachandran 
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 5, 2026, 16:28Jon Douglas: Imperial College London Review Maps Key Pathways in Autoimmune Thrombosis
-
Sep 5, 2026, 16:21Kelly Anderson: Bilateral Foot Pain and Purple Toes – Spotting Vascular Complications in Polycythemia Vera
-
Sep 5, 2026, 16:16Hazem Abosheaishaa: Beta-Blocker Selection Matters – Multi-Institutional Cohort Insights on PVT and Survival in Cirrhosis
-
Sep 5, 2026, 16:08Indre Ceponiene: Major Gaps in Secondary Cardiovascular Prevention Across Europe
-
Sep 5, 2026, 16:03W. Alberto Sifuentes Giraldo: Why Obstetric Cases Are Missed Under 2023 ACR/EULAR APS Criteria
-
Sep 5, 2026, 15:58Srikanth Nalla: A Case of Saddle Pulmonary Embolism
-
Sep 5, 2026, 15:55COPD-specific Pulmonary Embolism Diagnostic Strategy – Thrombosis and Haemostasis
-
Sep 5, 2026, 15:41Sam Tsimikas on Lp(a) HORIZON Topline Results – What Missed Endpoints Mean for Cardiovascular Risk
-
Sep 5, 2026, 15:32Stefano Garzon: SELUTION DeNovo HBR – Weren’t HBR Patients Supposed to Bleed More with DES?